August 3, 2022 – Siemens Healthineers AG today announces its results for the fiscal year 2022 third quarter that ended June 30, 2022.
Q3 Fiscal Year 2022
Continued very good growth in equipment orders, equipment book-to-bill ratio of 1.31
Due to markedly lower revenue from rapid COVID-19 antigen tests and a challenging environment, notably COVID-19 related lockdowns in China, comparable decline in revenue of 5.7% from a very good prior-year quarter with 38.9% growth; excluding rapid COVID-19 antigen tests, comparable revenue growth of 0.9%
Considerable comparable revenue growth of 8.2% at Varian and 5.8% in Advanced Therapies; Imaging with solid comparable revenue growth of 2.5%
Diagnostics showed a decline in comparable revenue of 23.9%, primarily due to a lower contribution from rapid COVID-19 antigen tests than in the outstanding prior-year quarter
Adjusted EBIT margin of 14.7% – negatively impacted by cost increases in particular for procurement and logistics, lockdowns in China, and reduced earnings from rapid COVID-19 antigen tests compared with the prior-year quarter
Adjusted basic earnings per share dropped 24% from the outstanding prior-year quarter to €0.43
Outlook for Fiscal Year 2022
Despite a more challenging environment, we confirm the expectation of comparable revenue growth between 5.5% and 7.5% and adjusted basic earnings per share between €2.25 and €2.35.
Bernd Montag, CEO of Siemens Healthineers AG:
»Once again, our team delivered a strong quarter despite an environment that was more than challenging. Supply-chain headwinds and pandemic-related lockdowns pushed out some sales into the next quarters, and cost increases burdened profits. Despite these factors, we confirm our outlook.«
